Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma

ConclusionLY01610 demonstrated manageable toxicity and promising anti-tumor activity in patients with advanced ESCC. Future clinical development of LY01610 as single agent or in combination with other anti-cancer agents in treating ESCC patients is warranted.Trial registrationNCT04088604 at ClinicalTrials.gov.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research